A controlled, assessor-blind, parallel groups, multicentre, multinational trial evaluating the immunogenicity of FE 999049 in repeated cycles of controlled ovarian stimulation in women undergoing an assisted reproductive technology programme

Trial Profile

A controlled, assessor-blind, parallel groups, multicentre, multinational trial evaluating the immunogenicity of FE 999049 in repeated cycles of controlled ovarian stimulation in women undergoing an assisted reproductive technology programme

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Follitropin delta (Primary) ; Follitropin alfa
  • Indications Female infertility
  • Focus Pharmacodynamics; Registrational
  • Acronyms ESTHER-2
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 27 Nov 2017 According to a Ferring Pharmaceuticals media release, based on the data from ESTHER programme, Swissmedic has approved Rekovelle(follitropin delta) for use in controlled stimulation for induction of the development of multiple follicles in women undergoing assisted reproductive technologies (ART), such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI).
    • 06 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 25 Jan 2017 This trial has been completed in Italy as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top